Investment Overview投资概况

Home / Investor Relations投资者关系 / Investment Overview投资概况

INVESTMENT HIGHLIGHTS

  • NASDAQ-listed China biopharmaceutical company focused on immuno-oncology and degenerative diseases.
  • China, a large market: 4x US population; 5M new cancer patients annually plus 57M Knee Osteoarthritis patients.
  • A leading biopharmaceutical innovator developing proprietary CAR-T constructs and allogeneic stem cell therapies.
  • Cutting-edge R&D and GMP facilities expanding capacity.
  • Lower valuation than peers given development progress, growth catalysts and addressable market size.
  • Seasoned management team with scientific, regulatory and financial expertise.
  • A SEC accelerated filer and a Nasdaq Global Market company.

Our strategy is to commercialize both home grown and partnered cellular medicine technologies in a safe and efficient manner, and achieve a leading position in the China specialty pharmaceutical market for cell therapeutics.  Our near term objective is to pursue successful clinical trials in China for our Stem Cell and Immuno-Oncology applications.  By applying U.S. Standard Operating Procedures (SOPs) and protocols and following authorized treatment plans in China we are differentiated with a first mover’s advantage and a fortified barrier to entry from competitors.

We believe that few competitors in China are as well-equipped as we are in the clinical trial development, diversified U.S. FDA protocol compliant manufacturing facilities, regulatory compliance and policy making participation, as well as a long-term presence in the U.S. with U.S.-based management and investor base.

We intend to continue our business development effort by adding other proven domestic and international biotechnology partners to monetize the China health care market.

公司优势

  • 丰富的产品线能够满足大型市场的需求
  • 经验丰富的管理团队和科研团队
  • 按照国际标准、美国FDA标准以及中国监管机构标准设计建造的中国GMP认证设施、
  • 中国第一家由国际质量管理系统认证公司SGS颁发ISO9001:2008认证的细胞医药公司

我们的战略是以安全及高效的方式对自主独立开发及合作研发的细胞医药技术进行商业化推广,树立在中国专业细胞治疗医药市场上的领先地位。

我们的近期目标是成功完成正在中国进行的干细胞和肿瘤免疫治疗应用的临床试验。通过采用美国标准操作规程(SOP)和协议,遵循在中国授权的治疗方案,我们将利用先发优势及增强潜在竞争对手的进入壁垒而脱颖而出。

我们精良的临床试验设备、多元化的符合美国FDA要求的生产设施、合规性和政策制定参与优势以及拥有基于美国的管理层和投资者基础的优势,使我们具备超越其他中国竞争对手的综合特质。

我们将不断与其他国内外生物技术企业建立合作关系,继续发展公司业务,在中国医疗保健市场中占据领导地位